USO 24333
A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive prostate cancer (mHSPC) (CJSB462C12201)
Disease Types: Genitourinary Cancer Research
Eligibility Requirements:
• Histological and/or cytological confirmation of
adenocarcinoma of the prostate
• Must have high-volume mHSPC
• ECOG ≤ 2
• Subjects that received treatment with a 2nd generation
ARPI for advanced/metastatic disease are excluded
• Treatment with a 1st generation ARPI in the context
of ADT initiation with a GnRH analog is allowed
• Subjects cannot be a candidate to receive or refuses
chemotherapy
• Subjects must have a castrate level of serum/plasma
testosterone
For more information on this trial CLICK HERE .
Available at: